Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 1 Completed
11 enrolled
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
Phase 1 Completed
120 enrolled
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
Phase 1 Completed
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
Phase 1 Completed
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
Phase 1 Completed
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase 1 Completed
7 enrolled
Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Phase 1 Completed
30 enrolled
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Phase 1 Completed
46 enrolled 11 charts
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
Phase 1 Completed
20 enrolled
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 1 Completed
20 enrolled
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
Phase 1 Completed
24 enrolled
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy
Phase 1 Completed
20 enrolled
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
Phase 1 Completed
35 enrolled
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
Phase 1 Completed
56 enrolled
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Phase 1 Completed
30 enrolled
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
Phase 1 Completed
29 enrolled
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
Phase 1 Completed
40 enrolled
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Phase 1 Completed
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia
Phase 1 Completed
80 enrolled
4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies
Phase 1 Completed
31 enrolled
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Phase 1 Completed
45 enrolled
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
Phase 1 Completed
18 enrolled
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
Phase 1 Completed
42 enrolled
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
Phase 1 Completed
30 enrolled
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
Phase 1 Completed
40 enrolled
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
5 enrolled
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
Phase 1 Completed
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
Phase 1 Completed
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
Phase 1 Completed
25 enrolled
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
Phase 1 Completed
31 enrolled
Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
Phase 1 Completed
24 enrolled
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
Phase 1 Completed
Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia
Phase 1 Completed
Pyroxamide in Treating Patients With Advanced Cancer
Phase 1 Completed
Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia
Phase 1 Completed
36 enrolled
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
Phase 1 Completed
25 enrolled
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia
Phase 1 Completed
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
Phase 1 Completed
24 enrolled
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
Phase 1 Completed
18 enrolled
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
Phase 1 Completed
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
36 enrolled
6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
Phase 1 Completed
25 enrolled
XK469R in Treating Patients With Refractory Hematologic Cancer
Phase 1 Completed
60 enrolled
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
Phase 1 Completed
48 enrolled
3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
Phase 1 Completed
48 enrolled
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
Phase 1 Completed
30 enrolled
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
Phase 1 Completed
30 enrolled
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
Phase 1 Completed
40 enrolled
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
Phase 1 Completed
30 enrolled